The 54 references in paper S. Avdeev N., С. Авдеев Н. (2014) “Дозированный порошковый ингалятор Турбухалер: особенности и место среди других ингаляционных устройств доставки // Dosing powder inhaler Turbuhaler, its characteristics and a place among other inhalation devices” / spz:neicon:pulmonology:y:2012:i:1:p:117-122

1
Laube B.L., Janssens H.M., de Jongh F.H. et al; European Respiratory Society; International Society for Aerosols in Medicine. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37: 1308–1331.
(check this in PDF content)
2
Lavorini F., Magnan A., Dubus J.C. et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir. Med. 2008; 102: 593–604.
(check this in PDF content)
3
Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемые при терапии заболеваний дыхательных путей. Рус. мед. журн. 2002; 10 (5): 255–261.
(check this in PDF content)
4
Wetterlin K.Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm. Res. 1988; 5: 506–508.
(check this in PDF content)
5
Wetterlin K.I.L. Design and function of Turbuhaler. In: Newman S.P., Moren F., Crompton G.K., eds. A new concept in inhalation therapy. London: Medicom; 1987.
(check this in PDF content)
6
Johnsen C.R., Weeke E.R.Turbuhaler: a new device for dry powder terbutaline inhalation. Allergy 1988; 43: 392–395.
(check this in PDF content)
7
Frijlink H.W., De Boer A.H.Dry powder inhalers for pulmonary drug delivery. Expert Opin. Drug Deliv. 2004; 1: 67–86.
(check this in PDF content)
8
Smith I.J., Parry-Billings M.The inhalers of the future? A review of dry powder devices on the market today. Pulm. Pharmacol. Ther. 2003; 16: 79–95.
(check this in PDF content)
9
Telko M.J., Hickey A.J. Dry powder inhaler formulation. Respir. Care 2005; 50: 1209–1227.
(check this in PDF content)
10
Авдеев С.Н.Порошковые ингаляторы. Атмосфера. Пульмонол. и аллергол. 2004; 4: 36–42.
(check this in PDF content)
11
Borgstrom L., Bisgaard H., O'Callaghan C., Pedersen S. Drypowder inhalers. In: Bisgaard H., O'Callaghan C., Smaldone G., ed. Drug delivery to the lung. New York: Marcel Dekker Inc.; 2002. 421–448.
(check this in PDF content)
12
Borgstrom L., Bondesson E., Moren F. et al. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur. Respir. J. 1994; 7: 69–73.
(check this in PDF content)
13
Pedersen S., Hansen O.R., Fuglsang G.Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch. Dis. Child. 1990; 65: 308–310.
(check this in PDF content)
14
Newman S.P., Busse W.W. Evolution of dry powder inhaler design, formulation, and performance. Respir. Med. 2002; 96: 293–304.
(check this in PDF content)
15
Lofdahl C.G., Arvidsson P., Bondesson E., Friberg K.Higher potency of salbutamol when given via Turbuhaler than via pressurized metered dose inhaler (pMDI). Allergy Clin. Immunol. News 1994; 6 (Suppl. 2): 383.
(check this in PDF content)
16
Matusiewicz S.P., Bollert F.G.E., Dewar M. et al. Ipratropium bromide given by Turbohaler®is more potent than when given by pressurized metered-dose inhaler (MDI). Thorax 1995; 50: 469.
(check this in PDF content)
17
Borgstrom L., Derom E., Stahl E. et al.The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am. J. Respir. Crit. Care Med. 1996; 153: 1636–1640.
(check this in PDF content)
18
Derom E., Thorsson L.Factors affecting the clinical outcome of aerosol therapy. In: Bisgaard H., O'Callaghan C., Smaldone G., ed. Drug delivery to the lung. New York: Marcel Dekker Inc.; 2002. 143–171.
(check this in PDF content)
19
Everard M.L., Dolovich M.B. In vivo measurements of lung dose. In: Bisgaard H., O'Callaghan C., Smaldone G. (Ed). Drug delivery to the lung. New York: Marcel Dekker Inc.;
(check this in PDF content)
20
2. 173–209. 20.Newman S.P., Moren F., Trofast E. et al.Terbutaline sulphate Turbuhaler effect of inhaled flow rate on drug deposition and efficacy. Int. J. Pharm. 1991; 74: 209–213.
(check this in PDF content)
21
Newman S.P. A comparison of lung deposition patterns between different asthma inhalers. J. Aerosol Med. 1995; 8 (Suppl. 3): S21–S27.
(check this in PDF content)
22
Thorsson L., Kenyon C., Newman S.P., Borgstrom L. Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int. J. Pharm. 1998; 168: 119–127.
(check this in PDF content)
23
Thorsson L., Edsbacker S., Conradson T.-B.Lung deposition of budesonide from Turbuhaler is twice that from a pressurised metered dose inhaler P-MDI. Eur. Respir. J. 1994; 7: 1839–1844.
(check this in PDF content)
24
Thorsson L., Edsbacker S., Kallen A., Lofdahl C-G.Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br. J. Clin. Pharmacol. 2001; 52: 529–538.
(check this in PDF content)
25
Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J. Allergy Clin. Immunol. 1998; 101: S434–S439.
(check this in PDF content)
26
Olsson B. Can in vitro measurements predict the lung deposition of dry-powder inhalers? J. Aerosol Med. 1997; 10: S13–S16.
(check this in PDF content)
27
Olsson B. Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers. J. Aerosol Med. 1995; 8 (Suppl. 3): 13–19.
(check this in PDF content)
28
Dolovich M.B. New propellant-free technologies under investigation. J. Aerosol Med. 1999; 12 (Suppl. 1): S9–S17.
(check this in PDF content)
29
Bisgaard H., Klug B., Sumby B.S., Burnell P.K.Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur. Respir. J. 1998; 11: 1111–1115.
(check this in PDF content)
30
Granlund K.M., Asking L., Lindblad T. et al.An in-vitro comparison of budesonide / formoterol and fluticasone / salmeterol in dry powder inhalers. Eur. Respir. J. 2000; 16 (Suppl. 31): 455s.
(check this in PDF content)
31
Fyrnys B., Stang N., Wolf-Heuss E. Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder inhaler device. Curr. Opin. Pulm. Med. 2001; 7 (Suppl. 1): S7–S11.
(check this in PDF content)
32
Srichana T., Martin G.P., Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur. J. Pharm. Sci. 1998; 7: 73–80.
(check this in PDF content)
33
Pavkov R., Singh D., Reitveld I. Concept1 (a new single dose dry powder inhaler) peak inspiratory flow rate study with COPD patients. Respir. Drug Deliv. 2008; 3: 683–686.
(check this in PDF content)
34
Svartengren K., Lindestad P., Svartengren M. et al.Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am. J. Respir. Crit. Care Med. 1995; 152: 32–37.
(check this in PDF content)
35
Borgstrom L. On the use of dry powder inhalers in situations perceived as constrained. J. Aerosol. Med. 2001; 14: 281–287.
(check this in PDF content)
36
McNeill R., Malcom G., Rhind Brown W.A comparison of expiratory and inspiratory flow rates in health and chronic pulmonary disease. Thorax 1959; 14: 25–31.
(check this in PDF content)
37
Brown P.H., Ning A.C., Greening A.P. et al.Peak inspiratory flow through Turbuhaler in acute asthma. Eur. Respir. J. 1995; 8: 1940–1941.
(check this in PDF content)
38
Dewar M.H., Jamieson A., McLean A., Crompton G.K. Peak inspiratory flow through Turbuhaler in chronic obstructive airways disease. Respir. Med. 1999; 93: 342–344.
(check this in PDF content)
39
Broek K.M., Wielders P.L.M.L., Creemers J.P.H.M., Smeenk F.W.J.M.Efficacy of formoterol Turbuhaler in the emergency treatment of patients with obstructive airway diseases. Respir. Med. 2008; 102: 579–585.
(check this in PDF content)
40
Nana A., Youngchaiyud P., Charoenratanakul S. et al. Highdose inhaled budesonide may substitute for oral therapy after an acute asthma attack. J. Asthma 1998; 35: 647–655.
(check this in PDF content)
41
Springer C., Stahl E., Schachter J., Avital A. Terbutaline given via Turbuhaler and in nebulised form in children with acute asthma. Eur. J. Clin. Res. 1996; 8: 163–169.
(check this in PDF content)
42
Phanareth K., Laursen L.C. Bricanyl Turbuhaler versus nebuliser in the treatment of patients with acute severe airways obstruction. Eur. Respir. J. 1999; 14 (Suppl. 30): 61s.
(check this in PDF content)
43
Balanag V.M., Yunus F., Yang P.-C., Jorup C. Efficacy and safety of budesonide / formoterol compared with salbutamol in the treatment of acute asthma. Pulm. Pharmacol. Ther. 2006; 19: 139–147.
(check this in PDF content)
44
Cazzola M., D'Amato M., Califano C. et al.Formoterol as dry powder oral inhalation compared with salbutamol metereddose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Clin. Ther. 2002; 24: 595–604.
(check this in PDF content)
45
Selroos O., Borgstrom L., Ingelf J. Use of dry powder inhalers in acute exacerbations of asthma and COPD. Ther. Adv. Respir. Dis. 2009; 3: 81–91.
(check this in PDF content)
46
Lindblat T., Granlund K.M., Rollwage U., Trofast E. Delivery chatracteristics of SymbicortТ TurbuhalerТ containing both budesonide and formoterol. Am. J. Respir. Crit. Care Med. 2001; 165: A863.
(check this in PDF content)
47
Lindsay D.A., Russell N.L., Thompson J.E. et al.A multicentre comparison of the efficacy of terbutaline Turbuhaler and salbutamol pressurized metered dose inhaler in hot, humid regions. Eur. Respir. J. 1994; 7: 342–345.
(check this in PDF content)
48
Palen J., Klein J.J., Schildkamp A.M. Comparison of a new multidose powder inhaler (Diskus / Accuhaler) and the Turbuhaler regarding preference and ease of use. J. Asthma 1998; 35: 147–152.
(check this in PDF content)
49
Wettengel R., Laurikainen K., Silvasti M. et al.Therapeutic equivalence and acceptability of two multidose powder inhalers in the treatment of asthma. Respiration 2000; 67: 77–82.
(check this in PDF content)
50
Lenney J., Innes J.A., Crompton G.K. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir. Med. 2000; 94: 496–500.
(check this in PDF content)
51
Serra-Batlles J., Plaza V., Badiola C., Morejion E. Inhalation Devices Study Group. Patient perception and acceptability of multidose dry powder inhalers: a randomized crossover comparison of Diskus / Accuhaler with Turbuhaler. J. Aerosol Med. 2002; 5: 59–64.
(check this in PDF content)
52
Spiegel P.I., Jenner F.A patient preference study comparing Turbuhaler with Discus, two multi-dose dry powder inhaler devices. Br. J. Clin. Res. 1997; 8: 33–35.
(check this in PDF content)
53
Giner J., Torrejon M., Ramos A. et al.Patient preference in the choice of dry powder inhalers. Arch. Bronconeumol. 2004; 40: 106–109.
(check this in PDF content)
54
Tordera M.P., Viejo J.L., Sanchos J. et al.Assessment of patient satisfaction and preferences with inhalers in asthma with the FSI-10 Questionnaire. Arch. Bronconeumol. 2008; 44: 346–352. Информация об авторе
(check this in PDF content)